NCT03167619View on ClinicalTrials.gov

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2022

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Olaparib Oral Product

olaparib 300mg twice daily

DRUG

Olaparib Oral Product in combination with Durvalumab

olaparib 300mg twice daily plus intravenous durvalumab every 28 days

Trial Locations (1)

27705

Duke University, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Duke University

OTHER